Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

The smart inhalers market is experiencing significant growth, driven by the increasing incidence of respiratory diseases like asthma and COPD, techno ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.

(Alliance News) - GSK PLC on Thursday said the US Food & Drug Administration has approved its asthma drug Nucala as an add-on maintenance treatment for adults with chronic obstructive pulmonary ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...